Benefits
Immune System Support
Vitamin C enhances immune function by supporting white blood cell activity and acting as an antioxidant to protect immune cells from oxidative stress. May reduce the duration and severity of common colds by about 8% in adults and 14% in children, though it doesn’t prevent colds outright (Hemilä & Chalker, 2013).
Antioxidant Protection
Neutralizes free radicals, reducing oxidative stress linked to chronic diseases like heart disease and cancer. May help protect against age-related conditions, such as macular degeneration (Evans & Lawrenson, 2017).
Collagen Formation
Essential for collagen synthesis, supporting skin, cartilage, bones, and wound healing. May improve skin health and reduce signs of aging by promoting elasticity (Pullar et al., 2017).
Improved Iron Absorption
Enhances non-heme (plant-based) iron absorption, which can help prevent or manage iron-deficiency anemia, especially in vegetarians (Hallberg et al., 1989).
Cardiovascular Health
May lower blood pressure and improve endothelial function, potentially reducing heart disease risk (Ashor et al., 2017). Some studies link higher vitamin C intake to reduced risk of stroke (Chen et al., 2013).
Potential Anti-Inflammatory Effects
High doses may reduce inflammation markers like C-reactive protein, which could benefit conditions like arthritis or metabolic syndrome (Juraschek et al., 2012).
Mechanism of action
Antioxidant Activity
Vitamin C is a potent water-soluble antioxidant that donates electrons to neutralize free radicals (reactive oxygen species, ROS) and reduce oxidative stress. It regenerates other antioxidants, like vitamin E, by reducing their oxidized forms (Carr & Frei, 1999). Protects cells, DNA, proteins, and lipids from oxidative damage, which is linked to aging, cancer, and cardiovascular diseases. This is particularly relevant in high-oxidative-stress conditions (e.g., smoking, intense exercise).
Collagen Synthesis:
Acts as a cofactor for prolyl and lysyl hydroxylases, enzymes critical for stabilizing collagen’s triple-helix structure. It donates electrons to maintain these enzymes’ iron in the reduced (Fe²⁺) state (Peterkofsky, 1991). Supports connective tissue formation, aiding skin, cartilage, bone health, and wound healing.
Neurotransmitter and Hormone Synthesis:
Serves as a cofactor for dopamine β-hydroxylase, which converts dopamine to norepinephrine, and for enzymes involved in peptide hormone maturation (e.g., oxytocin, vasopressin) (Englard & Seifter, 1986). Influences nervous system function and stress responses.
Enhancement of Iron Absorption
Reduces dietary ferric iron (Fe³⁺) to ferrous iron (Fe²⁺), which is more bioavailable, and forms chelates that keep iron soluble in the intestine (Hallberg et al., 1989). Increases non-heme iron absorption, helping prevent or treat iron-deficiency anemia, especially in plant-based diets.
Immune System Modulation
Enhances chemotaxis, phagocytosis, and oxidative burst in neutrophils, improving pathogen clearance. Protects immune cells from ROS damage during inflammation. Supports lymphocyte proliferation and function (Hemilä & Chalker, 2013). May reduce the duration and severity of infections like the common cold and support overall immune health.
Anti-Inflammatory and Cardiovascular Effects
Reduces pro-inflammatory markers (e.g., C-reactive protein) by scavenging ROS and modulating signaling pathways like NF-κB (Juraschek et al., 2012). Improves endothelial function by increasing nitric oxide bioavailability, which promotes vasodilation (Ashor et al., 2017). May lower blood pressure, improve vascular health, and reduce risk factors for heart disease and stroke.
Epigenetic Regulation
Acts as a cofactor for TET (ten-eleven translocation) enzymes, which demethylate DNA, and Jumonji-domain histone demethylases, influencing gene expression (Young et al., 2015). Potentially affects cellular differentiation and disease processes, though clinical implications are still under research.
Clinical trials
Randomized, double-blind, placebo-controlled trial (2019) in 167 patients with sepsis-related ARDS receiving high-dose IV vitamin C (50 mg/kg q6h) vs placebo. (Fowler et al. 2019, JAMA)
167 sepsis-ARDS patients.
PRIMARY ENDPOINTS NEGATIVE: no significant differences in SOFA score change, biomarkers of inflammation, or vascular injury. Secondary mortality benefit reported but should be interpreted cautiously after primary negative.
RCT (China, NCT04264533) in 56 critically ill COVID-19 pneumonia patients receiving high-dose IV vitamin C vs placebo. (Zhang et al. 2021, Ann Intensive Care)
56 critical COVID-19 patients.
Modest signals on certain inflammatory markers. NOT supportive of definitive COVID-19 treatment role.
Phase II RCT at University of Iowa (2024) in 34 patients with metastatic pancreatic cancer receiving high-dose IV vitamin C + chemotherapy.
34 metastatic pancreatic cancer patients.
Reported doubling of survival vs historical chemotherapy alone. CRITICAL CAVEAT: small phase II; pancreatic cancer historical comparator inevitably variable. Larger phase III needed before accepting clinical recommendation. CITATION CAVEAT: original citation was institutional news/info page, not peer-reviewed publication.
Phase II RCT at University of Iowa in glioblastoma patients receiving high-dose IV vitamin C.
Glioblastoma patients.
Modest survival/PFS signals. Larger validation needed.
International, randomized, placebo-controlled trial (2022, LOVIT) in 385 ICU patients with sepsis receiving IV vitamin C. (Lamontagne et al. 2022, NEJM)
385 septic ICU patients.
PRIMARY ENDPOINT NEGATIVE: no benefit vs placebo for composite of death or persistent organ dysfunction at 28 days. POSSIBLE HARM SIGNAL — increased risk of organ failure or death. Important large rigorous negative trial — combined with VITAMINS, ATESS — effectively ENDED enthusiasm for high-dose IV vitamin C in sepsis.
Systematic review and meta-analysis (2024) of 6 RCTs (through November 2023) of vitamin C in CAP.
Pooled across 6 CAP RCTs.
Modest reduction in pneumonia duration in some subgroups. Effect sizes modest.
Systematic review and meta-analysis (2017) of RCTs of vitamin C for AF prevention in cardiac surgery and ICU.
Pooled across AF prevention RCTs.
Modest reduction in AF incidence in cardiac surgery patients. Adjunctive role.
Double-blind RCT in 78 mild-to-moderate AD patients receiving vitamin C, E, and alpha-lipoic acid combination.
78 AD patients.
Modest cognitive signals. Multi-ingredient. Modern AD landscape (lecanemab, donanemab) — supplements not established treatment. CITATION CAVEAT: original citation was institutional news/info page, not peer-reviewed publication.
2011 meta-analysis of 13 RCTs in healthy individuals with elevated serum uric acid.
Pooled across uric acid RCTs.
Vitamin C modestly lowered serum uric acid (~0.35 mg/dL). NOTE: subsequent Stamp 2013 NEGATIVE in actual gout patients — vitamin C did NOT prevent gout flares. Uric acid lowering ≠ gout flare prevention.
Meta-analysis (2014) of 7 RCTs in 62,619 participants on vitamin C supplementation for cancer prevention.
Pooled across 7 cancer prevention RCTs.
PRIMARY ENDPOINT NEGATIVE: vitamin C did NOT reduce overall cancer incidence vs control. SU.VI.MAX, ATBC, similar trials negative for vitamin C cancer chemoprevention.
Double-blind RCT (Iran 2021) in 31 critical COVID-19 patients with 500 mg/day oral vitamin C.
31 ICU COVID-19 patients.
Modest signals. Very small trial.
Phase I/II Mayo Clinic trial of IV vitamin C as adjunct to pazopanib in metastatic sarcoma.
Metastatic sarcoma patients.
Phase I/II ongoing; tolerability and signals being assessed.
Phase II Iowa trial of high-dose IV vitamin C in non-small cell lung cancer.
NSCLC patients.
Phase II ongoing. Iowa group has substantial program in IV vitamin C oncology adjunct research; remains research-only context. CITATION CAVEAT: original citation was institutional news/info page, not peer-reviewed publication.